During fall 2020, many U.S. kindergarten through grade 12 (K-12) schools closed campuses and instituted remote learning to limit in-school transmission of SARS-CoV-2, the virus that causes COVID-19 (1,2). A New Jersey grade 9-12 boarding school with 520 full-time resident students, 255 commuter students, and 405 faculty and staff members implemented a comprehensive mitigation strategy that included universal masking, testing, upgraded air-handling equipment to improve ventilation, physical distancing of ≥6 ft, contact tracing, and quarantine and isolation protocols to prevent and control transmission of SARS-CoV-2 among students, faculty, and staff members. Mandatory twice-weekly screening using real-time reverse transcription-polymerase chain reaction (RT-PCR) testing of all students and staff members during August 20-November 27, 2020, resulted in the testing of 21,449 specimens. A total of 19 (5%) of 405 faculty and staff members and eight (1%) of 775 students received positive test results; only two identified cases were plausibly caused by secondary transmission on campus. Comprehensive mitigation approaches including frequent testing and universal masking can help prevent outbreaks in in-person high school settings even when community transmission is ongoing. During August 20-November 27, 2020, a private boarding school in New Jersey implemented rigorous, comprehensive strategies to prevent introduction and transmission of SARS-CoV-2, including requiring students to quarantine for 2 weeks before arriving, and, upon arrival, to provide documentation of a negative RT-PCR test result performed within 7-10 days before campus arrival (Box). Upon opening in the fall, the school conducted twice-weekly RT-PCR screening of all students, faculty, and staff members during August 20-November 27. Students' specimens were tested by using Broad Laboratories anterior nasal swab, high-throughput version of the CDC 2019-nCoV RT-PCR Diagnostic Panel, validated in accordance with guidance by the College of American Pathologists (issued on March 19, 2020) and the Food and Drug Administration (issued on February 29, 2020).* Faculty and staff member saliva samples were processed * https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19emergency-use-authorizations-medical-devices/vitro-diagnostics-euas †